Study to Evaluate the Safety and Effectiveness of REAL INTELLIGENCE™ CORI™ in Unicondylar Knee Arthroplasty (UKA) Procedures

NCT ID: NCT04797897

Last Updated: 2025-03-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-12
• Study Completion Date: 2024-02-16

Brief Summary

This is a prospective study to demonstrate the safety and effectiveness of CORI and to register CORI in China mainland.

Detailed Description

This is a prospective, multi-center, randomized study to demonstrate the safety and effectiveness of CORI. In addition, the study will support regulatory approval by the National Medical Products Administration (NMPA) in China.

The study will have two arms, the investigational group will be total knee arthroplasty (TKA) using CORI, the comparison group will be conventional approach with conventional manual instrumentation.

Conditions

Non-inflammatory Degenerative Joint Disease; Osteoarthritis; Avascular Necrosis; Requires Correction of Functional Deformity; Fracture, Knee

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CORI UKA

Subjects in need for unicondylar knee arthroplasty (UKA) as decided by their doctor and treated with CORI.

Group Type: EXPERIMENTAL

CORI

Intervention Type: DEVICE

unicondylar knee arthroplasty (UKA) treated with CORI

Conventional UKA

Subjects in need for unicondylar knee arthroplasty (UKA) as decided by their doctor and treated with conventional approach with conventional manual instrumentation.

Group Type: ACTIVE_COMPARATOR

Conventional

Intervention Type: DEVICE

unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation

Interventions

CORI

unicondylar knee arthroplasty (UKA) treated with CORI

Intervention Type: DEVICE

Conventional

unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject is a suitable candidate for a UKA procedure using CORI and a compatible S+N Knee implant system.

2. Subject requires a cemented UKA as a primary indication that meets any of the following conditions:

1. Non-inflammatory degenerative joint disease, including osteoarthritis

2. Avascular necrosis

3. Requires correction of functional deformity

4. Requires treatment of fractures that were unmanageable using other techniques

3. Subject is of legal age to consent and considered skeletally mature (≥ 18 years of age at the time of surgery).

4. Subject agrees to consent to and to follow the study visit schedule (as defined in the study protocol and informed consent form), by signing the Ethics Committee (EC) or Institutional Review Board (IRB) approved informed consent form.

5. Subject plans to be available through one (1) year postoperative follow-up.

6. Applicable routine radiographic assessment if possible.

Exclusion Criteria

1. Subject receives a UKA on the index joint as a revision for a previously failed surgery, or need for complex implants, or any other implant than a standard UKA (e.g. stems, augments, or custom made devices).

2. Subject has been diagnosed with post-traumatic arthritis

3. Subject receives simultaneous bilateral UKA OR a unilateral UKA with contralateral TKA.

4. Subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the investigator:-Contralateral primary TKA or UKA, however, the subject can only have one knee enrolled in this study.

5. Subject does not understand the language used in the Informed Consent Form.

6. Subject does not meet the indication or is contraindicated for UKA according to specific S+N knee system's Instructions For Use (IFU).

7. Subject has active infection or sepsis (treated or untreated).

8. Subject is morbidly obese with a body mass index (BMI) greater than 40.

9. Subject is pregnant or breast feeding at the time of surgery.

10. Subject, in the opinion of the Investigator, has advanced osteoarthritis or joint disease at the time of surgery and was better suited for an alternate procedure.

11. Subject currently enrolled in another orthopedic clinical trial study.

12. Subject has a condition(s) that may interfere with the UKA survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease, or an active, local infection).

13. Subject in the opinion of the Investigator has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, intellectual disability, drug or alcohol abuse.

14. Subject, in the opinion of the Investigator, has a neuromuscular disorder that prohibited control of the index joint.

15. Subject is a prisoner or meets the definition of a Vulnerable Subject per ISO 14155:2020 Section 3.55.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Smith & Nephew, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Patricia McCracken

Role: STUDY_DIRECTOR

Smith & Nephew, Inc.

Locations

Northern Hospital

Epping, , Australia

The Prince of Wales Hospital

Shatin, , Hong Kong

North Shore Hospital

Auckland, , New Zealand

Countries

Australia; Hong Kong; New Zealand

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CORI.2019.06

Identifier Type: -

Identifier Source: org_study_id